Emergent BioSolutions (NYSE:EBS) Earns “Buy” Rating from HC Wainwright

Emergent BioSolutions (NYSE:EBS)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a report issued on Friday,Benzinga reports. They currently have a $15.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price points to a potential upside of 49.55% from the company’s current price.

Other equities research analysts have also issued research reports about the stock. Rodman & Renshaw reissued a “buy” rating and issued a $16.00 price target on shares of Emergent BioSolutions in a report on Friday, September 13th. Benchmark raised their target price on Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Finally, StockNews.com lowered Emergent BioSolutions from a “buy” rating to a “hold” rating in a research report on Saturday, December 28th.

Emergent BioSolutions Stock Performance

NYSE:EBS opened at $10.03 on Friday. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. Emergent BioSolutions has a fifty-two week low of $1.42 and a fifty-two week high of $15.10. The firm has a market cap of $543.47 million, a PE ratio of -2.45 and a beta of 1.60. The business has a 50 day moving average price of $9.33 and a 200-day moving average price of $9.08.

Institutional Investors Weigh In On Emergent BioSolutions

Several institutional investors and hedge funds have recently modified their holdings of EBS. Meeder Asset Management Inc. bought a new position in Emergent BioSolutions in the second quarter worth about $41,000. Vanguard Personalized Indexing Management LLC bought a new position in shares of Emergent BioSolutions in the 2nd quarter worth approximately $93,000. Stifel Financial Corp bought a new position in shares of Emergent BioSolutions in the 3rd quarter worth approximately $96,000. Morse Asset Management Inc purchased a new position in shares of Emergent BioSolutions in the 2nd quarter valued at approximately $97,000. Finally, FORA Capital LLC bought a new stake in shares of Emergent BioSolutions during the third quarter valued at approximately $103,000. 78.40% of the stock is owned by hedge funds and other institutional investors.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.